Ontology highlight
ABSTRACT: Unlabelled
Regorafenib is an oral multitargeted kinase inhibitor with potent antiangiogenic activity. In this phase I trial we evaluated the safety, pharmacokinetics, and efficacy of regorafenib with cisplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancers (nsNSCLCs). Nine patients enrolled before premature termination of the study. Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months). Regorafenib had acceptable tolerability and minor pharmacokinetic interactions in combination with standard doses of cisplatin and pemetrexed in patients with advanced nsNSCLCs.Background
The combination of bevacizumab, an antiangiogenesis agent, with cytotoxic chemotherapy improves su
SUBMITTER: Hellmann MD
PROVIDER: S-EPMC4750397 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature